Refractory, advanced Mycosis fungoides Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Refractory advanced Mycosis fungoides / Mycosis fungoides refractory / Refractory Mycosis Fungoides

IndicationStatusPhase
DBCOND0024424 (Refractory, advanced Mycosis fungoides)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03063632Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary SyndromeTreatment